BiotechTube
Peroxitech

Peroxitech

Cambridge, United States· Est.
peroxitech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Founded in 2016, Peroxitech is a preclinical-stage biotech targeting acute lung injury and related conditions through a novel peptide technology. The company's science is based on foundational research from the University of Pennsylvania's Institute for Environmental Medicine, co-invented by its scientific founders. With recent NIH grant funding for both ALI and lung transplant organ viability, Peroxitech is advancing its lead program while exploring adjacent applications in critical care and transplantation. The leadership combines deep pulmonary disease expertise with pharmaceutical industry experience in operations and commercialization.

Acute Lung InjuryOrgan Transplantation

Technology Platform

Novel peptide therapeutic targeting a newly discovered signaling pathway in the oxidative injury cascade.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The significant unmet need in Acute Lung Injury/ARDS and the critical bottleneck in lung transplant organ preservation represent two substantial market opportunities.
Success in either area could lead to a transformative therapy with high clinical and economic value.
The technology's potential applicability to other conditions involving oxidative injury offers further pipeline expansion possibilities.

Risk Factors

The company faces high scientific risk as its novel peptide must prove safe and effective in future clinical trials.
As a preclinical, private company, it carries substantial financing risk, requiring significant capital to advance.
The competitive landscape for ALI/ARDS, though lacking approved drugs, includes other investigational approaches with a history of clinical failure.

Competitive Landscape

The ALI/ARDS therapeutic landscape is challenging with no approved pharmacologic therapies, but includes numerous failed candidates and other companies exploring anti-inflammatory, anti-oxidant, and barrier-protection approaches. In organ preservation, the standard is cold static storage; competitors include companies developing ex-vivo lung perfusion (EVLP) systems and therapeutic additives to preservation solutions. Peroxitech's peptide could be a disruptive, pharmacologic approach within both fields.

More companies in Small Molecule Drugs →More companies in United States →